What is Peptoniphilus (anaerobic Gram-positive bacterium)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Peptoniphilus infections should be treated with antibiotics effective against anaerobic bacteria, such as metronidazole, as recommended by guidelines for the treatment of intra-abdominal infections 1. When considering the treatment of Peptoniphilus infections, it is essential to note that these bacteria are anaerobic, Gram-positive organisms that can cause infections in various sites, including the abdomen, skin, and urogenital tract.

  • Key characteristics of Peptoniphilus species include their ability to ferment peptones and produce butyric acid.
  • They are normally found in the human gut, urogenital tract, and skin, but can act as opportunistic pathogens in certain circumstances.
  • Infections caused by Peptoniphilus can be challenging to diagnose due to their strict anaerobic growth requirements and biochemical properties, often necessitating specialized laboratory techniques or molecular methods for identification. According to the guidelines for the diagnosis and management of complicated intra-abdominal infection in adults and children, coverage for obligate anaerobic bacilli, such as Peptoniphilus, should be provided for distal small bowel, appendiceal, and colon-derived infections, as well as for more proximal gastrointestinal perforations in the presence of obstruction or paralytic ileus 1.
  • The recommended antibiotic regimens for the treatment of community-acquired intra-abdominal infections of mild-to-moderate severity include metronidazole in combination with other agents, such as cefazolin, cefuroxime, ceftriaxone, cefotaxime, levofloxacin, or ciprofloxacin 1.
  • The choice of antibiotic should be guided by local microbiologic data, cost advantage, allergies, and formulary availability, as well as susceptibility testing when available. It is crucial to consider the potential for antimicrobial resistance among anaerobic bacteria, including Peptoniphilus, when selecting an antibiotic regimen, and to avoid the use of broad-spectrum agents when possible to minimize the risk of promoting resistance 1.

From the Research

Peptoniphilus Overview

  • Peptoniphilus asaccharolyticus is a Gram-positive anaerobic coccus that forms part of the normal flora and human commensals of the skin, genitourinary system, and gut 2.
  • It can cause opportunistic infections in immunocompromised patients and is frequently isolated as part of polymicrobial spectra 2.

Infection and Treatment

  • Anaerobic infections, including those caused by Peptoniphilus, can occur at all body sites, including the central nervous system, oral cavity, head and neck, chest, abdomen, pelvis, skin, and soft tissues 3, 4.
  • Treatment of anaerobic infections is complicated by the slow growth of these organisms, their polymicrobial nature, and the growing resistance of anaerobes to antimicrobials 5, 3, 4.
  • Effective antimicrobials against anaerobic organisms include metronidazole, carbapenems, combinations of a beta-lactam and a beta-lactamase inhibitor, chloramphenicol, tigecycline, and clindamycin 5, 3, 4.
  • Metronidazole is still considered the drug of choice for the treatment of anaerobic infections due to its low cost, good activity against pathogenic anaerobic bacteria, favorable pharmacokinetic and pharmacodynamic properties, and minor adverse effects 6.

Specific Case of Peptoniphilus asaccharolyticus

  • A case report described septic shock, renal abscess, and bacteremia due to Peptoniphilus asaccharolyticus in a woman with nephrosis and diabetes mellitus 2.
  • The underlying diseases of the host and the removal of the double J tube were significant predisposing factors in this infection 2.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Antimicrobials therapy of anaerobic infections.

Journal of chemotherapy (Florence, Italy), 2016

Research

Antimicrobial treatment of anaerobic infections.

Expert opinion on pharmacotherapy, 2011

Research

Treatment of anaerobic infection.

Expert review of anti-infective therapy, 2007

Research

Metronidazole is still the drug of choice for treatment of anaerobic infections.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.